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Cytokine-based and antibody-targeted immunotherapies
have both been important approaches in the treatment
of malignant cancers. However, combinational therapies
of cytokines and tumor-targeting antibodies remain to
be further explored, especially in advanced solid tumors.
In this study, C57BL/6 mice bearing established subcu-
taneous B16F10 melanoma were treated with mouse
melanoma targeting anti-gp75 monoclonal antibody
(mAb), TA99, combined with interleukin (IL)-15 based
superagonist ALT-803. This soluble protein complex
consists of an IL-15 superagonist mutant (IL-15N72D)
associated with an IL-15 receptor a Sushi domain -
human IgG1 Fc fusion protein. Compared to native IL-
15, ALT-803 possesses superior in vivo biologic activity
for stimulating NK and CD8+ memory T cells. The
combined ALT-803+TA99 therapy significantly
exceeded either monotherapy in inhibiting melanoma
tumor growth (p < 0.001) and prolonging survival (p <
0.01) of B16F10 tumor-bearing mice. Through immune
cell depletion studies and immunophenotyping of per-
ipheral cells as well as tumor-infiltrating leukocyte sub-
sets, we found that ALT-803 enhances TA99-mediated
antitumor immunity through activation of NK cells and
expansion of the CD8+CD44high memory T cell arm. In
contrast, CD4+ T cells were shown to play more of a
suppressive role in the therapeutic effect of ALT-803
+TA99, possibly through involvement of regulatory
T cells or ALT-803-mediated induction of PD-L1 on
CD4+ T cells in the periphery and tumor microenviron-
ment. Addition of anti-PD-L1 mAb to ALT-803+TA99
therapy resulted in a further increase in antitumor activ-
ity against subcutaneous B16F10 tumors. Furthermore,
tumor-bearing mice that survived due to ALT-803
+TA99 combination therapy exhibited long term antitu-
mor memory against B16F10 tumor cell rechallenge.
Immune-depletion studies revealed that this antitumor
memory was associated with CD4+ T cells, CD8+ T cells
and NK cells. Our findings suggest a therapeutic oppor-
tunity for ALT-803 in combination with tumor-targeting
antibodies to simultaneously augment targeted antitu-
mor activities of therapeutic antibodies and induce a
long-term vaccinal effect which will provide durable
responses in the treated host.
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